Psilocybin Versus Ketamine in Treatment-Resistant Depression

NCT ID: NCT05383313

Last Updated: 2022-05-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-05-01
• Study Completion Date: 2025-04-30

Brief Summary

The main goal is to compare the antidepressant effects of psilocybin and ketamine in patients with TRD versus the antidepressant inactive substance midazolam. The primary endpoint will be the antidepressant effect on the Montgomery- Asberg Depression Rating Scale (MADRS) 24 hours after treatment, the key secondary endpoints being the duration of antidepressant effect, the number of responses and remissions, and the time to standard antidepressant treatment during 3 months of observation. The exploratory part of the study aims to monitor changes in the functional brain states using simultaneous EEG / fMRI, before treatment versus 1 day and 1 week after. Based on literature data and recent data from healthy volunteers who participated in a previous study with psilocybin, the investigator will correlate antidepressant effects of drugs (using psychometric scales and reactions to emotionally salient stimuli (eye tracker)) with entropy and functional connectivity measures. Finally the investigator will explore the role of plasmatic neurobiological biomarkers in depression (BDNF, prolactin, ACTH and oxytocin).

Detailed Description

The main aim of the study is to verify the efficacy and safety of a single dose of psilocybin 20 mg in the treatment of TRD in adults in a randomized clinical trial with active comparator ketamine 200 mg (rapid onset acting antidepressant) and negative control midazolam 5 mg (drug with no antidepressant properties). Primary objective: 1) verification of the rapid antidepressant effect of psilocybin compared to ketamine using the MADRS scale at 24 hours. Secondary objectives: 1) on days 3, 7 and 14 and 3, 4, 5, 6, 8 and 12 weeks after application of the substances, evaluate / compare: a) the duration of effects of both substances using the MADRS scale b) antidepressant effects according to the subjective evaluation of patients - QIDS scale. c) response rate (50% reduction on the MADRS scale) and remission (MADRS ? 10). 2) time to return of depressive symptoms defined according to the criteria for the use of antidepressants within 12 weeks 3) safety profile of study medication Exploratory objectives: 1) Evaluate the antidepressant effect depending on: a) the intensity of acute psychological effects assessed using the subjective scale of 5D-ASCs and the objective scale of BPRS, b) depending on the retrospective assessment of persistent effects using the Persisting effects scale, c) the degree of eye contact with negative and neutral emotion faces measured by eye-tracking before and after treatment (on days 1 and 7). 2) To evaluate the neurobiology of the antidepressant effect in relation to: a) plasma levels of the major metabolite of psilocin, markers of neuroplasticity, antidepressant effect and stress (BDNF, prolactin, oxytocin, ACTH) at 90 min, 3, and 6 h after administration of study medication compared to pre-administration levels, b) changes in resting-state brain activity (connectivity, entropy) measured by simultaneous EEG / fMRI functional imaging methods before and after 1 and 7 days after treatment.

Conditions

Treatment Resistant Depression

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: QUADRUPLE

Study Groups

Psilocybin

25 mg, orally (capsule), single administration

Group Type: EXPERIMENTAL

Psilocybin

Intervention Type: DRUG

Effect of psilocybin on treatment-resistant depression

Ketamine

250 mg, orally (capsule), single administration

Group Type: ACTIVE_COMPARATOR

Ketamine Hydrochloride

Intervention Type: DRUG

Effect of ketamine on treatment-resistant depression

Midazolam

5 mg, orally (capsule), single administration

Group Type: PLACEBO_COMPARATOR

Midazolam Ph. Eur 9.0

Intervention Type: DRUG

Effect of midazolam on treatment-resistant depression

Interventions

Psilocybin

Effect of psilocybin on treatment-resistant depression

Intervention Type: DRUG

Ketamine Hydrochloride

Effect of ketamine on treatment-resistant depression

Intervention Type: DRUG

Midazolam Ph. Eur 9.0

Effect of midazolam on treatment-resistant depression

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Men and women aged 18-65

2. Diagnosis of moderate to severe depressive disorder without psychotic symptoms - ICD-10 criteria F32.1-2 or F33.1-2 and at the same time MADRS score > 20

3. The duration of the current depressive episode is at least 3 months and maximum 2 years

4. Treatment-resistant depression defined as:

1. Failure of at least 2 and at most 4 adequate treatments (6 weeks of full therapeutic dose of antidepressant or adequate non-pharmacological treatment - e.g. psychotherapy, neurostimulation treatment, phototherapy, etc.) within the current depressive episode, using at least 2 types of antidepressants with different pharmacological mechanisms of action (augmentation is taken as a second treatment) or

2. Intolerance of 2 different treatments and 1 adequate treatment or

3. Intolerance of 3 different antidepressant treatments.

5. Ability to understand the study protocol and to be able to complete all study visits and examinations as defined per protocol.

6. Participants in a clinical trial of childbearing potential must agree to the use of prescribed contraceptive methods for the duration of the study

Exclusion Criteria

1. Severe psychiatric comorbidity (axis I MINI, ICD-10 F0.X - F99.X, the intensity of the disorder will be clinically assessed by the study clinician)

2. The current depressive phase is severe with psychotic symptoms (ICD-10: F32.3, F33.3)

3. MADRS suicidality score (item 10)> 4

4. Duration of the current depressive episode longer than 2 years

5. Current drug or alcohol dependence (ICD-10: F17.x) with the exception of tobacco and with the exception of abstinence lasting more than 2 years

6. Claustrophobia, inability to undergo MR examination

7. Pregnancy or breast-feeding or plan to become pregnant within the next 12 months

8. Intracranial hypertension, pulmonary hypertension, uncorrected arterial hypertension (BP> 150/100 mmHg)

9. Condition after stroke, myocardial infarction in the last 6 months

10. Heart failure

11. Untreated or decompensated hyperthyroidism

12. Glaucoma

13. Severe respiratory failure or acute respiratory depression

14. History of seizures

15. Other serious somatic disease or any other circumstance in which a significant increase in blood pressure would pose a serious threat to health (to be assessed by the study clinician)

16. Pacemaker

17. Metal implants made of MR incompatible materials

18. Regular use of medication that could interact with psilocybin (to be assessed by the investigator)

19. Regular use of antipsychotics with 5-HT2A receptor antagonist activity or discontinuation of their use for less than 14 days (eg risperidone, olanzapine, clozapine, quetiapine, ziprasidone)

20. Current use of monoamine oxidase inhibitors (MAOIs)

21. Previous experience with psilocybin, hallucinogenic mushrooms or ketamine is possible in a maximum of 10% of patients. This experience must not be during the last 12 months or during the current depressive episode.

22. Recent use of antidepressants with a direct antagonistic effect on 5-HT2A receptors such as SARI and tetracyclic antidepressants (eg trazodone, mirtazapine, mianserin) or discontinuation of their use for less than 14 days

23. Electroconvulsive therapy in the previous 3 months

24. Daily use of benzodiazepine anxiolytics higher than the equivalent of 10 mg diazepam

25. Allergy to any of the components of study drugs

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Czech Health Research Council

UNKNOWN

Sponsor Role: collaborator

Czech Clinical Research Infrastructure Network

UNKNOWN

Sponsor Role: collaborator

National Institute of Mental Health, Czech Republic

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

National Institute of Mental Health

Klecany, , Czechia

Site Status: RECRUITING

Countries

Czechia

Central Contacts

Vivian Winkler, MD

Role: CONTACT

vivian.winkler@nudz.cz

+420773137373

Nikola Leca, PhD

Role: CONTACT

nikola.leca@nudz.cz

+420608049831

Facility Contacts

Vivian Winkler, MD

Role: primary

vivian.winkler@nudz.cz

773137373

Nikola Leca, PhD

Role: backup

nikola.leca@nudz.cz

608049831

Other Identifiers

PSIKET_001CZE

Identifier Type: -

Identifier Source: org_study_id